Results 81 to 90 of about 12,085 (139)

Comment on "Dexamethasone-sparing on days 2-4 with combined palonosteron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)". [PDF]

Br J Cancer
Celio L, Antonuzzo A, Aapro MS.
europepmc   +1 more source

Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study. [PDF]

J Clin Med
Bozbulut UB, Cengiz T, Özet A.
europepmc   +1 more source

Cellular metabolism of substance P produces neurokinin-1 receptor peptide agonists with diminished cyclic AMP signaling.

Am J Physiol Cell Physiol
Kriska T, Natarajan J, Herrnreiter A, Park SK, Pfister SL, Thomas MJ, Widiapradja A, Levick SP, Campbell WB.   +8 more
europepmc   +1 more source

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial). [PDF]

Br J Cancer
Minatogawa H, Izawa N, Shimomura K, Arioka H, Iihara H, Sugawara M, Morita H, Mochizuki A, Nawata S, Mishima K, Tsuboya A, Miyaji T, Honda K, Yokomizo A, Hashimoto N, Yanagihara T, Endo J, Kawaguchi T, Furuya N, Sone Y, Inada Y, Ohno Y, Katada C, Hida N, Akiyama K, Ichikura D, Konomatsu A, Ogura T, Yamaguchi T, Nakajima TE.   +29 more
europepmc   +1 more source

Neurokinin-1 receptors on the afferents to the raphe

, 2016
Hafizi, S, Boothman, L, Totterdall, S, Grasby, P, Sharp, T   +4 more
openaire   +2 more sources

Electroacupuncture on Baihui (DU20) and Xuehai (SP10) acupoints alleviates psoriatic inflammation by regulating neurotransmitter substance P- Neurokinin-1 receptor signaling. [PDF]

J Tradit Complement Med
Qi C, Feng F, Guo J, Liu Y, Guo X, Meng Y, Di T, Hu X, Wang Y, Zhao N, Zhang X, Wang Y, Zhao J, Li P.   +13 more
europepmc   +1 more source

Substance P and the neurokinin 1 receptor

, 2009
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safety of neurokinin-1 receptor antagonists

Expert Opinion on Drug Safety, 2013
The substance P (SP)/neurokinin (NK)-1 receptor system is involved in many pathological processes. NK-1 receptor antagonists have many promising therapeutic indications. However, the only NK-1 receptor antagonist used in clinical practice is the drug aprepitant and its intravenously administered prodrug, fosaprepitant.
Miguel, Muñoz, Rafael, Coveñas
openaire   +2 more sources

Neurokinin-1 Receptor Resensitization Precedes Receptor Recycling

The Journal of Pharmacology and Experimental Therapeutics, 2005
Following agonist binding, neurokinin-1 receptors undergo rapid desensitization followed by internalization and recycling. Desensitization requires receptor phosphorylation but does not require internalization, whereas resensitization is thought to require internalization and recycling.
V J, Bennett, S A, Perrine, M A, Simmons
openaire   +2 more sources